COMPOUND PROFILE / SMALL MOLECULES
AZD5004 / ECC5004.
Research draftAZD5004, previously ECC5004 and also called elecoglipron, is an oral small-molecule GLP-1 receptor agonist.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
AZD5004, previously ECC5004 and also called elecoglipron, is an oral small-molecule GLP-1 receptor agonist.
Mechanism
It activates GLP-1 receptors without being a peptide.
Human research
First-in-human research and the randomised VISTA trial provide clinical development evidence.
Preclinical & other research
Receptor experiments and nonclinical studies characterised target activity.
Safety & unknowns
Gastrointestinal effects and longer-term safety need formulation-specific evaluation.
Regulatory status
Investigational candidate; do not transfer another GLP-1 product's authorisation.
Reported use & evidence
The supplied AZD5004 / ECC5004 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.